News from viacyte, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Sep 10, 2014, 15:21 ET
ViaCyte logo.  (PRNewsFoto/ViaCyte, Inc.)

ViaCyte, Inc. Awarded $16.6 Million Accelerated Development Pathway Grant from CIRM to Expand Clinical Development of its VC-01™ Diabetes Therapy Candidate

 ViaCyte, Inc., a privately held regenerative medicine company developing a stem cell-derived islet replacement therapy for the treatment of...

Aug 21, 2014, 09:00 ET
ViaCyte logo.  (PRNewsFoto/ViaCyte, Inc.)

ViaCyte, Inc. Announces Signing of Rights Agreement with Janssen Research & Development LLC.

ViaCyte, Inc., a privately held regenerative medicine company announced today that it has entered into a Rights Agreement with Janssen Research...

Aug 19, 2014, 09:00 ET
ViaCyte logo.  (PRNewsFoto/ViaCyte, Inc.)

ViaCyte, Inc. Announces FDA Acceptance of IND to Commence Clinical Trial of VC-01™ Candidate Cell Replacement Therapy for Type 1 Diabetes

ViaCyte, Inc., a privately-held regenerative medicine company, announced today that the U.S. Food and Drug Administration ("FDA") has accepted the...

Aug 08, 2014, 10:09 ET
ViaCyte logo.  (PRNewsFoto/ViaCyte, Inc.)

ViaCyte, Inc. Raises $5.4 Million in a Private Financing to Support Clinical Development of its Cell Therapy Product VC-01™ for Insulin-Dependent Diabetes

 ViaCyte, Inc., a privately held regenerative medicine company developing a stem cell-derived islet replacement therapy for the treatment of...

Jul 17, 2014, 09:00 ET
ViaCyte logo.  (PRNewsFoto/ViaCyte, Inc.)

ViaCyte Files Investigational New Drug Application and Device Master File with FDA for Novel Cell Replacement Therapy Product Candidate Designed to Treat Patients with Type 1 Diabetes

ViaCyte, Inc., a privately held regenerative medicine company developing a cell replacement therapy for the treatment of diabetes, today announced...

Jul 08, 2014, 09:00 ET
ViaCyte logo.  (PRNewsFoto/ViaCyte, Inc.)

ViaCyte Achieves Significant Milestone with ISO 13485:2003 Certification for its Encaptra Drug Delivery System

 ViaCyte, Inc. ("ViaCyte"), a privately held regenerative medicine company developing a cell therapy for treatment of type I diabetes, today...

May 29, 2014, 09:00 ET
ViaCyte logo.  (PRNewsFoto/ViaCyte, Inc.)

ViaCyte and Asterias Biotherapeutics Settle Patent Dispute

 ViaCyte, Inc., a regenerative medicine company focused on developing a cell replacement therapy for the treatment of patients with...

Feb 06, 2014, 09:00 ET
ViaCyte logo.  (PRNewsFoto/ViaCyte, Inc.)

JDRF to Provide Additional Support for Upcoming Clinical Trial of ViaCyte's Encapsulated Cell Therapy for Type 1 Diabetes

JDRF, the world's largest non-profit supporter of type 1 diabetes (T1D) research, and ViaCyte, Inc., a leading regenerative medicine company,...

Dec 19, 2013, 09:00 ET
ViaCyte logo.  (PRNewsFoto/ViaCyte, Inc.)

ViaCyte Appoints Mark Foletta, former CFO of Amylin, to its Board of Directors

 ViaCyte, Inc., a leading regenerative medicine company developing a transformative cell therapy for treatment of diabetes, announced today...

Dec 02, 2013, 13:00 ET
ViaCyte logo.  (PRNewsFoto/ViaCyte, Inc.)

ViaCyte to Present at the 25th Piper Jaffray Healthcare Conference

 ViaCyte, Inc., a leading regenerative medicine company developing a transformative cell therapy for the treatment of diabetes, today...

Oct 29, 2013, 09:00 ET
ViaCyte logo.  (PRNewsFoto/ViaCyte, Inc.)

ViaCyte Granted Over 20 Patents in 2013 Further Establishing the Company as a Leader in the Field of Regenerative Medicine

ViaCyte, Inc., a leading regenerative medicine company focused on developing new approaches to treat major diseases through the application of a...

Oct 16, 2013, 11:56 ET
ViaCyte logo.  (PRNewsFoto/ViaCyte, Inc.)

ViaCyte to Present at the JDRF 8th Annual T1D Global Path to a Cure Symposium

ViaCyte, Inc., a leading regenerative medicine company developing a transformative cell therapy for the treatment of diabetes, today announced...

Oct 10, 2013, 14:12 ET
ViaCyte logo.  (PRNewsFoto/ViaCyte, Inc.)

ViaCyte To Present Update On VC-01™ Combination Product Development At 2013 Stem Cell Meeting On The Mesa

ViaCyte, Inc. announced today that an update on the Company's progress toward a transformative stem cell-derived cell therapy for the treatment of...

Jul 10, 2013, 06:00 ET

ViaCyte, Inc. raises $10.6 Million in a Private Financing to Support Clinical Development of its Cell Therapy Product for Insulin Dependent Diabetes

 ViaCyte, Inc., a leading regenerative medicine company focused on developing new approaches to treat major diseases through the application...

Jan 31, 2013, 09:00 ET
ViaCyte logo.  (PRNewsFoto/ViaCyte, Inc.)

ViaCyte's Role as a Leading Cell Therapy Company Bolstered with the Issuance of 20 Patents in 2012

ViaCyte, Inc., a leading regenerative medicine company focused on developing new approaches to treat major diseases through the application of a...

Oct 29, 2012, 09:05 ET
ViaCyte logo.  (PRNewsFoto/ViaCyte, Inc.)

ViaCyte Appoints Steve Altman to its Board of Directors

 ViaCyte, Inc., a leading regenerative medicine company developing a transformative cell therapy for treatment of diabetes, announced today...

Oct 26, 2012, 09:05 ET
ViaCyte logo.  (PRNewsFoto/ViaCyte, Inc.)

ViaCyte Receives $10.1 Million Strategic Partnership Award from CIRM to Continue Development of Diabetes Therapy

 ViaCyte, Inc., a leading regenerative medicine company developing a transformative cell therapy for treatment of diabetes, announced today...

Jun 15, 2012, 06:00 ET

ViaCyte Appoints Dr. Paul Laikind Chief Executive Officer

 ViaCyte, Inc. today announced the appointment of seasoned entrepreneur, Paul Laikind, Ph.D., as President & Chief Executive Officer. ...

Aug 09, 2011, 06:00 ET

ViaCyte Announces Executive Management Changes

ViaCyte, Inc. today announced changes to its  executive management team, including the appointment of Allan Robins, Ph.D., as Acting Chief...

Jun 15, 2011, 13:51 ET

ViaCyte Names Michael Scott Vice President, Device Research & Development

ViaCyte, Inc. today announced the appointment of Michael J. Scott, Ph.D. as Vice President, Device Research and Development, reporting to John...